The broad range of NF-κB activity in tissues that do not participate in immunity per se and the contribution of NF-κB activation to metabolic disease pathogenesis (Hotamisligil et al. 1993; Cai et al. 2004, 2005; Arkan et al. 2005) raise important questions concerning the genomic effectors of NF-κB activity within the brain, immune tissue, and other peripheral metabolic organs such as the liver. This evidence concerns the gene NFKB1 and Other metabolic disease.